Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced new employee inducement grants approved on April 1, 2025. The company granted 50,600 non-qualified stock options and 8,250 restricted stock units to three new non-executive employees who joined in March 2025.
The stock options will vest 25% after one year, with the remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in therapeutic resistance treatments, has announced its participation in two major investor conferences in April 2025.
The company will present at two events:
- Needham's 24th Annual Healthcare Conference - Company overview presentation scheduled for Monday, April 7, 2025, at 1:30 p.m. ET
- Stifel 2025 Virtual Targeted Oncology Forum - Fireside chat participation on Wednesday, April 9, 2025, at 2:00 p.m. ET
Both events will be webcasted and accessible through ORIC's investor relations website, with replays available for 90 days post-event.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced that preclinical data for ORIC-944, their PRC2 inhibitor for prostate cancer treatment, will be presented at the 2025 AACR Annual Meeting in Chicago (April 25-30, 2025).
The preclinical results show ORIC-944 as a potent, selective, and orally bioavailable allosteric PRC2 inhibitor with properties supporting once-daily dosing. The drug demonstrated robust PRC2 inhibition in prostate cancer models, enhancing luminal cell state and increasing androgen receptor (AR) signaling. The treatment restricts cellular plasticity and creates an AR-dependent state, showing synergy with AR pathway inhibitors (ARPIs) in both ARPI-sensitive and resistant settings.
A phase 1b trial combining ORIC-944 with ARPIs is currently ongoing in metastatic prostate cancer (NCT05413421).
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced new employee inducement grants approved on March 3, 2025. The company granted 26,450 non-qualified stock options and 4,300 restricted stock units to three new non-executive employees who joined in February 2025.
The stock options will vest 25% on the first anniversary of the Grant Date, with the remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals has announced focused registrational clinical development plans for its lead programs ORIC-944 and ORIC-114, along with an extended cash runway into 2027. The company plans to initiate its first Phase 3 trial for ORIC-944 in metastatic castration resistant prostate cancer (mCRPC) in 1H 2026, while ORIC-114's registrational development will focus on first-line non-small cell lung cancer (NSCLC) with anticipated initiation in 2026.
Key milestones include combination dose escalation data for ORIC-944 expected in 1H and 2H 2025, and comprehensive NSCLC data for ORIC-114 in 2H 2025. The company reported $256 million in cash and investments as of December 31, 2024, extending their projected cash runway from late 2026 to 2027 under the refined operating plan.
ORIC Pharmaceuticals reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical programs. The company reported cash and investments of $256 million, expected to fund operations into late 2026. Key developments include encouraging early safety and efficacy data for ORIC-944 in metastatic prostate cancer treatment and a clinical trial collaboration with Johnson & Johnson for ORIC-114.
Financial results show R&D expenses increased to $114.1 million for 2024, up from $85.2 million in 2023. G&A expenses rose to $28.8 million in 2024 from $25.6 million in 2023. The company secured a $125 million private placement financing and expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the granting of inducement equity awards to two new non-executive employees who joined the company in January 2025. The grants, approved on February 3, 2025, include 29,600 non-qualified stock options and 4,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal annual installments. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three major investor conferences in February 2025. The company will engage in fireside chats at the following events:
- Jones Research Precision Medicine Day on February 3 at 12:30 p.m. ET
- Guggenheim Securities SMID Cap Biotech Conference on February 5 at 1:30 p.m. ET
- Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 12:00 p.m. ET
Live webcasts of these discussions will be accessible through the investor section of ORIC's website at www.oricpharma.com, with replays available for 90 days after each event.
ORIC Pharmaceuticals has reported encouraging early Phase 1b combination data for ORIC-944 in treating metastatic castration-resistant prostate cancer (mCRPC). The trial showed deep PSA decreases, with 3 of 6 patients achieving confirmed PSA50 responses and 2 achieving PSA90 responses. The treatment demonstrated favorable safety with primarily Grade 1 and 2 adverse events.
The company entered a clinical collaboration with Johnson & Johnson to evaluate ORIC-114 combined with amivantamab for first-line NSCLC treatment. ORIC expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
Following a $125 million private placement financing, ORIC's cash position stood at $282.4 million as of September 30, 2024, expected to fund operations into late 2026.
ORIC Pharmaceuticals announced a clinical supply agreement with Janssen Research & Development to evaluate ORIC-114 in combination with amivantamab for the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This Phase 1b trial is expected to begin in Q1 2025, with initial data anticipated by mid-2026.
The trial aims to assess the safety and tolerability of the combination therapy and determine the recommended Phase 2 dose (RP2D). ORIC will sponsor the trial, while Johnson & Johnson will supply amivantamab.
ORIC retains the development and commercial rights to ORIC-114 and may expand its use with other agents. The company highlighted that ORIC-114 has shown promising systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC. The trial will further explore its efficacy in the first-line setting, both as a monotherapy and in combination with amivantamab.
In 2024, ORIC completed the monotherapy dose escalation portion of the Phase 1b trial for ORIC-114 in patients with advanced solid tumors. Based on these data, two provisional RP2D levels (80 mg and 120 mg QD) were selected for further evaluation.